Perrigo Company plc develops, manufactures and distributes healthcare products. The company operates primarily in four segments: Consumer Healthcare, Nutritionals, Rx Pharmaceutical and Active Pharmaceutical Ingredients. It also provides animal health products. The company operates primarily in the United States, the United Kingdom, Mexico, Israel, Australia, Canada, China and Latin America. Perrigo Company plc formerly known as Perrigo Company is headquartered in Ireland.
Industry sector: Medical
Sector classification: Pharmaceutical preparations
Deep Learning based analysis and prediction model for Perrigo Company (PRGO) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.
Model is in the production pipeline since Sept. 30, 2015.
Market data for PRGO model training are being downloaded from the
Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are
accounted for in this model in the form of the historical data coincided with outbreaks and other
global events in the past used to train ML prediction model for PRGO.
Model is being retrained on a daily basis.
| Float | 131M |
| P/E | 15.45 |
| Shares Outstanding | 141M |
| % Held by Insiders | 6.90% |
| % Held by Institutions | 79.12% |
| EPS (last reported FY) | $4.93 |
| EPS (last reported Q) | $1.28 |
| EPS, estimated (last reported Q) | $1.24 |
| Total revenues | $5 B |
| Net income | $0 B |